These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22760303)

  • 21. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
    Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
    J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
    Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
    Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
    Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
    Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay.
    Hodgson DC; Brierley JD; Tsang RW; Panzarella T
    Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management.
    Li P; Zhang A; Liu Y; Xu C; Tang L; Yuan H; Liu Q; Wang X; Feng D; Wang L; Huang G; Song S
    Thyroid; 2019 Jan; 29(1):93-100. PubMed ID: 30351248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
    Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
    Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiated thyroid carcinomas in childhood: clinicopathologic results of 26 patients.
    Ozkan E; Soydal C; Araz M; Kucuk NO
    J Pediatr Endocrinol Metab; 2011; 24(9-10):739-42. PubMed ID: 22145466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
    Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
    J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
    Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
    Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
    Durante C; Haddy N; Baudin E; Leboulleux S; Hartl D; Travagli JP; Caillou B; Ricard M; Lumbroso JD; De Vathaire F; Schlumberger M
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2892-9. PubMed ID: 16684830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
    Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
    J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma.
    Tamilia M; Al-Kahtani N; Rochon L; Hier MP; Payne RJ; Holcroft CA; Black MJ
    Nucl Med Commun; 2011 Mar; 32(3):212-20. PubMed ID: 21191314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
    Patel SS; Goldfarb M
    J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer.
    M El-Refaei S; W Yassin S; Salman K; Al Munshy T; Al-Ezzi M; M Al-Sayed Y; Abd Elkareem Husseni M
    Nucl Med Commun; 2015 Feb; 36(2):114-9. PubMed ID: 25350460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
    Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.